Not catalog-first. Target-first.
Four binder chassis, chosen strictly on the merits of your binding interface.
Fab / scFv designs with established manufacturing and regulatory precedent.
Single-domain VHH framework with camelid-derived loop flexibility.
De novo scaffolds offering high stability and precise interface targeting.
Constrained macrocycles with cell permeability and oral bioavailability potential.
Embedded within the prestigious IRCM, our physical laboratory bridges the critical gap between in silico generation and in vitro reality.
Rapid, large-scale screening of computationally engineered binders. Executing proprietary validation workflows within native cellular contexts.
Direct integration with top-tier microscopy, genomics, proteomics, immunology, and oncology resources, enabling accelerated development pipelines.
